Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Harbeck · SciRah

Researcher profile · Semantic Scholar

N. Harbeck

Share profile

N. Harbeck — researcher profile on SciRah

h-index: 115
Works: 1,153
Citations: 62K

Most-cited papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
S. Modi, W. Jacot, T. Yamashita, J. Sohn +34 more
2022New England Journal of Medicine2,030 citations Open access
Semantic Scholar
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
S. Johnston, M. Toi, J. O'Shaughnessy, P. Rastogi +20 more
2022The Lancet Oncology459 citations Open access
Semantic Scholar
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
M. Cristofanilli, H. Rugo, S. Im, D. Slamon +16 more
2022Clinical Cancer Research175 citations Open access
Semantic Scholar
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer
U. Nitz, O. Gluz, S. Kuemmel, M. Christgen +23 more
2022Journal of Clinical Oncology113 citations
Semantic Scholar
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP
J. Litton, M. Regan, L. Pusztai, H. Rugo +23 more
2023Journal of Clinical Oncology95 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022
N. Ditsch, Achim Wöcke, M. Untch, C. Jackisch +42 more
2022Breast Care76 citations Open access
Semantic Scholar
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
D. Pinato, J. Aguilar-Company, D. Ferrante, G. Hanbury +143 more
2022The Lancet Oncology73 citations Open access
Semantic Scholar
St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer – A Brief Summary of the Consensus Discussion
M. Balić, C. Thomssen, M. Gnant, N. Harbeck
2023Breast Care62 citations Open access
Semantic Scholar
Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis.
V. Salvestrini, Kyubo Kim, S. Caini, S. Alkner +18 more
2023Radiotherapy and Oncology56 citations Open access
Semantic Scholar
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
U. Nitz, O. Gluz, M. Graeser, M. Christgen +17 more
2022The Lancet Oncology56 citations
Semantic Scholar
Clinical validity and clinical utility of Ki67 in early breast cancer
H. Kreipe, N. Harbeck, M. Christgen
2022Therapeutic Advances in Medical Oncology44 citations Open access
Semantic Scholar
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples
James E. Barrett, Chiara M. S. Herzog, Allison Jones, O. Leavy +21 more
2022Nature Communications43 citations Open access
Semantic Scholar
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
A. de Gregorio, W. Janni, T. Friedl, U. Nitz +16 more
2022British Journal of Cancer41 citations Open access
Semantic Scholar
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
L. Pusztai, C. Denkert, J. O'Shaughnessy, J. Cortés +15 more
2022Journal of Clinical Oncology40 citations
Semantic Scholar
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
O. Gluz, U. Nitz, M. Christgen, S. Kuemmel +16 more
2023JAMA Oncology36 citations Open access
Semantic Scholar
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
N. Harbeck, U. Nitz, M. Christgen, S. Kuemmel +23 more
2023Journal of Clinical Oncology35 citations
Semantic Scholar
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
C. Becherini, L. Visani, S. Caini, I. Bhattacharya +19 more
2023Cancer Treatment Reviews32 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023
M. Thill, C. Kolberg-Liedtke, U. Albert, M. Banys-Paluchowski +43 more
2023Breast Care32 citations Open access
Semantic Scholar
De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.
O. Gluz, U. Nitz, C. Kolberg-Liedtke, A. Prat +21 more
2022Clinical Cancer Research31 citations Open access
Semantic Scholar
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
A. Cortellini, J. Tabernero, U. Mukherjee, R. Salazar +123 more
2023The Lancet Oncology29 citations Open access
Semantic Scholar
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
F. Schettini, S. Venturini, M. Giuliano, M. Lambertini +26 more
2022Cancer Treatment Reviews29 citations Open access
Semantic Scholar
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
K. Hutchinson, Jessica W. Chen, H. Savage, T. Stout +10 more
2023Genome Medicine24 citations Open access
Semantic Scholar
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
D. Juric, K. Kalinsky, S. Im, E. Ciruelos +11 more
2023Journal of Clinical Oncology23 citations Open access
Semantic Scholar
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
Sophie A. Mueller, I. Grote, S. Bartels, L. Kandt +8 more
2023Modern Pathology23 citations Open access
Semantic Scholar
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey
Fatima Cardoso, J. Rihani, V. Harmer, N. Harbeck +9 more
2023The Oncologist22 citations Open access
Semantic Scholar
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry
A. Cortellini, A. Gennari, F. Pommeret, G. Patel +98 more
2022Journal of the National Cancer Institute20 citations Open access
Semantic Scholar
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
C. Kolberg-Liedtke, F. Feuerhake, M. Garke, M. Christgen +16 more
2022Breast Cancer Research20 citations Open access
Semantic Scholar
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
C. Barrios, S. Saji, N. Harbeck, H. Zhang +7 more
2022npj Breast Cancer19 citations Open access
Semantic Scholar
App-Based Lifestyle Coaching (PINK!) Accompanying Breast Cancer Patients and Survivors to Reduce Psychological Distress and Fatigue and Improve Physical Activity: A Feasibility Pilot Study
Josefine Wolff, P. Wuelfing, A. König, Brigitte Ehrl +5 more
2023Breast Care18 citations
Semantic Scholar
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
S. Hurvitz, T. Bachelot, G. Bianchini, N. Harbeck +12 more
2022Future Oncology18 citations Open access
Semantic Scholar
Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock
J. Barrett, Chiara M. S. Herzog, Y. Kim, Thomas E. Bartlett +11 more
2022Genome Biology18 citations Open access
Semantic Scholar
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
S. Paluch-Shimon, P. Neven, J. Huober, I. Çiçin +14 more
2023Therapeutic Advances in Medical Oncology17 citations Open access
Semantic Scholar
Diagnostic effectiveness of [^18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
G. Bottoni, F. Fiz, M. Puntoni, F. Matteucci +13 more
2023European Journal of Nuclear Medicine and Molecular Imaging17 citations
Semantic Scholar
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
C. Corti, G. Antonarelli, C. Valenza, E. Nicolò +6 more
2022European Journal of Cancer17 citations
Semantic Scholar
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis—Results from the Adjuvant SUCCESS A Trial
E. Trapp, P. Fasching, T. Fehm, A. Schneeweiss +11 more
2022Cancers16 citations Open access
Semantic Scholar
Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04
A. Prat, S. Modi, J. Tsurutani, D. Cameron +11 more
2023Cancer Research15 citations
Semantic Scholar
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Bolivar Arboleda, R. Bartsch, E. de Azambuja, E. Hamilton +8 more
2022The Oncologist15 citations Open access
Semantic Scholar
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
C. Geyer, A. Bardia, N. Harbeck, M. Rimawi +12 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022
M. Thill, D. Lüftner, C. Kolberg-Liedtke, U. Albert +42 more
2022Breast Care13 citations Open access
Semantic Scholar
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
M. Aapro, F. Cardoso, G. Curigliano, A. Eniu +8 more
2022Breast12 citations Open access
Semantic Scholar
Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL
M. Thill, M. Zahn, A. Welt, E. Stickeler +10 more
2023Breast Cancer Research and Treatment10 citations Open access
Semantic Scholar
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
M. Tagliamento, A. Gennari, M. Lambertini, R. Salazar +49 more
2023Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
S. Bruzas, O. Gluz, N. Harbeck, P. Schmid +13 more
2022npj Breast Cancer10 citations Open access
Semantic Scholar
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
M. Graeser, O. Gluz, C. Biehl, D. Ulbrich-Gebauer +23 more
2022Clinical Cancer Research10 citations Open access
Semantic Scholar
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC)
A. Bardia, P. Schmid, N. Harbeck, M. Rimawi +13 more
2022Cancer Research10 citations
Semantic Scholar
Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses
P. Schmid, J. Cortés, R. Dent, L. Pusztai +26 more
2022Cancer Research9 citations
Semantic Scholar
ABC6 Consensus: Assessment by a Group of German Experts
D. Lüftner, P. Fasching, R. Haidinger, N. Harbeck +6 more
2022Breast Care9 citations Open access
Semantic Scholar
Abstract PD10-11: Keyriched-1- A prospective, multicenter, open label, neoadjuvant phase ii single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype
S. Kuemmel, O. Gluz, M. Reinisch, Athina Kostara +19 more
2022Cancer Research9 citations
Semantic Scholar
Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
B. Aktas, T. Fehm, M. Welslau, V. Müller +20 more
2022Geburtshilfe und Frauenheilkunde8 citations Open access
Semantic Scholar
CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.
N. Harbeck, P. Fasching, R. Wuerstlein, T. Degenhardt +13 more
2023Journal of Clinical Oncology7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

O. Gluz×15
Invite
O. Gluz — researcher profile on SciRah
H. Kreipe×13
Invite
H. Kreipe — researcher profile on SciRah
R. Wuerstlein×12
Invite
R. Wuerstlein — researcher profile on SciRah
U. Nitz×11
Invite
U. Nitz — researcher profile on SciRah

×11

Invite

M. Christgen — researcher profile on SciRah

Invite

R. Kates — researcher profile on SciRah

Invite

H. Rugo — researcher profile on SciRah

Invite

P. Schmid — researcher profile on SciRah

C. Kolberg-Liedtke×9

Invite

C. Kolberg-Liedtke — researcher profile on SciRah

Invite

A. Prat — researcher profile on SciRah

Invite

P. Fasching — researcher profile on SciRah

Invite

M. Braun — researcher profile on SciRah